Patent Office Mulls Voucher For Fast-Track Re-exam If Firms Create "Humanitarian" Technology
Executive Summary
The Patent and Trademark Office was inspired by FDA’s priority review voucher program to encourage companies to develop drugs for neglected tropical diseases. PTO is considering a similar strategy to reward patent owners who develop and license technologies with humanitarian uses.
You may also be interested in...
FDA Priority Review Voucher Redemption Fee Set At $4.6 Million In Fiscal 2011
Users of the voucher, designed as an incentive for developing therapies for tropical diseases, will pay the fee on top of the standard $1.5 million PDUFA user fee.
Sanofi Set To Seek $442 Million From Apotex For Plavix Infringement
District court denies Apotex's request to stay the award of damages; Patent Office reexamination finds Plavix patent is valid.
Priority Review Vouchers One Step Closer, But Congress Must Act Again
FDA will not be able to review applications covered by a priority review voucher until it receives Congressional authorization to collect a special user fee to support the program, the agency says in a draft guidance on the new incentive for pharmaceutical companies